Ralph D Sanderson

List of Publications by Year
in descending order

110 papers	9,969 citations	28736 57 h-index	39744 98 g-index
110 all docs	110 docs citations	110 times ranked	9125 citing authors

#	Article	IF	Citations
1	Induction of heparanase 2 (Hpa2) expression by stress is mediated by ATF3. Matrix Biology, 2022, 105, 17-30.	1.5	7
2	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. Journal of Virology, 2022, 96, e0005722.	1.5	14
3	Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth. Cancer Research, 2020, 80, 57-68.	0.4	32
4	Heparanase promotes myeloma stemness and in vivo tumorigenesis. Matrix Biology, 2020, 88, 53-68.	1.5	24
5	Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression. Journal of Histochemistry and Cytochemistry, 2020, 68, 823-840.	1.3	43
6	Therapy-induced chemoexosomes: Sinister small extracellular vesicles that support tumor survival and progression. Cancer Letters, 2020, 493, 113-119.	3.2	5
7	Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function. Cells, 2020, 9, 2038.	1.8	11
8	Significance of host heparanase in promoting tumor growth and metastasis. Matrix Biology, 2020, 93, 25-42.	1.5	21
9	Forty Years of Basic and Translational Heparanase Research. Advances in Experimental Medicine and Biology, 2020, 1221, 3-59.	0.8	48
10	Heparanase: A Dynamic Promoter of Myeloma Progression. Advances in Experimental Medicine and Biology, 2020, 1221, 331-349.	0.8	19
11	Fibronectin on the Surface of Extracellular Vesicles Mediates Fibroblast Invasion. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 279-288.	1.4	68
12	Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling. Matrix Biology, 2019, 75-76, 160-169.	1.5	123
13	Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy. Haematologica, 2018, 103, e469-e472.	1.7	90
14	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biology, 2018, 65, 104-118.	1.5	172
15	Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression. Trends in Biochemical Sciences, 2018, 43, 18-31.	3.7	117
16	Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics. Chemical Reviews, 2018, 118, 9152-9232.	23.0	253
17	Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS Journal, 2017, 284, 42-55.	2.2	182
18	Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Advances, 2017, 1, 2375-2385.	2.5	8

#	Article	IF	Citations
19	Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer. F1000Research, 2016, 5, 1541.	0.8	38
20	Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth. Cancer Research, 2016, 76, 4981-4993.	0.4	48
21	Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biology, 2016, 55, 22-34.	1.5	70
22	Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug Resistance Updates, 2016, 29, 54-75.	6.5	180
23	Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes and Control, 2016, 27, 81-91.	0.8	35
24	Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. Journal of Biological Chemistry, 2016, 291, 1652-1663.	1.6	219
25	Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget, 2016, 7, 1598-1607.	0.8	76
26	Shed Syndecan-1 Translocates to the Nucleus of Cells Delivering Growth Factors and Inhibiting Histone Acetylation. Journal of Biological Chemistry, 2015, 290, 941-949.	1.6	55
27	Heparanase is a host enzyme required for herpes simplex virus-1 release from cells. Nature Communications, 2015, 6, 6985.	5.8	128
28	Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 276-300.	3.3	96
29	Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study. Blood, 2015, 126, 3246-3246.	0.6	10
30	Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse. Matrix Biology, 2014, 35, 215-222.	1.5	62
31	Heparan sulfate in the nucleus and its control of cellular functions. Matrix Biology, 2014, 35, 56-59.	1.5	93
32	Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone, 2013, 57, 10-17.	1.4	43
33	Heparanase: Multiple functions in inflammation, diabetes and atherosclerosis. Matrix Biology, 2013, 32, 220-222.	1.5	53
34	The heparanase/syndecanâ€1 axis in cancer: mechanisms and therapies. FEBS Journal, 2013, 280, 2294-2306.	2.2	156
35	Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes. Journal of Biological Chemistry, 2013, 288, 10093-10099.	1.6	277
36	Shed syndecanâ€1 drives tumor progression by binding to the cell surface and translocating to the nucleus. FASEB Journal, 2013, 27, 595.1.	0.2	1

#	Article	IF	Citations
37	Heparanase Enhances the Insulin Receptor Signaling Pathway to Activate Extracellular Signal-regulated Kinase in Multiple Myeloma. Journal of Biological Chemistry, 2012, 287, 41288-41296.	1.6	44
38	Heparan Sulfate Chains of Syndecan-1 Regulate Ectodomain Shedding. Journal of Biological Chemistry, 2012, 287, 9952-9961.	1.6	104
39	Heparanase Regulates Response to Proteasomal Inhibition in Myeloma. Blood, 2012, 120, 4902-4902.	0.6	0
40	Runx2 Transcription Factor Regulates Heparanase-Induced Bone Resorption in Multiple Myeloma. Blood, 2012, 120, 567-567.	0.6	1
41	Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. Journal of Cellular and Molecular Medicine, 2011, 15, 1013-1031.	1.6	484
42	SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis. Clinical Cancer Research, 2011, 17, 1382-1393.	3.2	217
43	Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Expression and Activity. Journal of Biological Chemistry, 2011, 286, 6490-6499.	1.6	104
44	Heparanase-mediated Loss of Nuclear Syndecan-1 Enhances Histone Acetyltransferase (HAT) Activity to Promote Expression of Genes That Drive an Aggressive Tumor Phenotype. Journal of Biological Chemistry, 2011, 286, 30377-30383.	1.6	98
45	Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood, 2010, 115, 2449-2457.	0.6	198
46	Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. Journal of Bone and Mineral Research, 2010, 25, 1295-1304.	3.1	35
47	Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS Journal, 2010, 277, 3890-3903.	2.2	148
48	Heparanase Enhances Local and Systemic Osteolysis in Multiple Myeloma by Upregulating the Expression and Secretion of RANKL. Cancer Research, 2010, 70, 8329-8338.	0.4	60
49	Heparanase Regulates Levels of Syndecan-1 in the Nucleus. PLoS ONE, 2009, 4, e4947.	1.1	91
50	Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in Vivo. Journal of Biological Chemistry, 2009, 284, 26085-26095.	1.6	78
51	Heparanase: busy at the cell surface. Trends in Biochemical Sciences, 2009, 34, 511-519.	3.7	216
52	Myeloma Bone Disease. Journal of Bone and Mineral Research, 2009, 24, 1783-1788.	3.1	11
53	Heparanase Promotes Osteolysis by Upregulating RANKLâ€“ A Novel Role for Heparanase in Multiple Myeloma.. Blood, 2009, 114, 2821-2821.	0.6	0
54	Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clinical and Experimental Metastasis, 2008, 25, 149-159.	1.7	109

#	Article	IF	Citations
55	Nonâ€enzymatic glycation of type I collagen diminishes collagenâ€"proteoglycan binding and weakens cell adhesion. Journal of Cellular Biochemistry, 2008, 104, 1684-1698.	1.2	57
56	Heparanase Stimulation of Protease Expression Implicates It as a Master Regulator of the Aggressive Tumor Phenotype in Myeloma. Journal of Biological Chemistry, 2008, 283, 32628-32636.	1.6	174
57	The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo. Blood, 2008, 112, 246-246.	0.6	1
58	Heparanase Promotes the Osteolytic Phenotype in Multiple Myeloma. Blood, 2008, 112, 841-841.	0.6	0
59	Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo. Blood, 2008, 112, 5165-5165.	0.6	0
60	Heparanase Enhances Syndecan-1 Shedding. Journal of Biological Chemistry, 2007, 282, 13326-13333.	1.6	237
61	Non-Anticoagulant Heparins and Inhibition of Cancer. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 195-203.	0.5	146
62	The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood, 2007, 110, 2041-2048.	0.6	122
63	A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.. Blood, 2007, 110, 1502-1502.	0.6	3
64	Expression of Soluble Syndecan-1 or Heparanase by Myeloma Cells Enhances Levels of Angiogenic Growth Factors Present in Endothelial Cells.. Blood, 2006, 108, 3448-3448.	0.6	0
65	Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood, 2005, 105, 1303-1309.	0.6	130
66	Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies. Journal of Cellular Biochemistry, 2005, 96, 897-905.	1.2	146
67	Identification of an Invasion Regulatory Domain within the Core Protein of Syndecan-1. Journal of Biological Chemistry, 2005, 280, 3467-3473.	1.6	46
68	HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo. Journal of Biological Chemistry, 2005, 280, 40066-40073.	1.6	122
69	Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases. Cancer Research, 2005, 65, 5778-5784.	0.4	101
70	Dynamic Remodeling of Syndecan-1 Structure Regulates. Trends in Glycoscience and Glycotechnology, 2005, 17, 263-270.	0.0	0
71	Extracellular Endosulfatases (Sulfs) Inhibit Myeloma Tumor Growth In Vivo.. Blood, 2005, 106, 3386-3386.	0.6	3
72	Heparanase Upregulates Synthesis and Expression of Syndecan-1 (CD138) - A Novel Growth Regulatory Loop for Myeloma Tumors.. Blood, 2005, 106, 625-625.	0.6	0

#	Article	IF	Citations
73	Heparanase Degrades Syndecan-1 and Perlecan Heparan Sulfate. Journal of Biological Chemistry, 2004, 279, 8047-8055.	1.6	129
74	Heparan sulfate proteoglycans and heparanaseâ€"partners in osteolytic tumor growth and metastasis. Matrix Biology, 2004, 23, 341-352.	1.5	186
75	Heparanase Promotes the Spontaneous Metastasis of Myeloma Cells to Bone.. Blood, 2004, 104, 635-635.	0.6	1
76	Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytoma. Journal of Cutaneous Pathology, 2003, 30, 18-22.	0.7	12
77	Heparan Sulfate Regulates Targeting of Syndecan-1 to a Functional Domain on the Cell Surface. Journal of Biological Chemistry, 2003, 278, 12888-12893.	1.6	25
78	The epidermal growth factorâ€"like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood, 2003, 102, 2916-2924.	0.6	207
79	Vitronectin's Basic Domain is a Syndecan Ligand which Functions in trans to Regulate Vitronectin Turnover. Cell Communication and Adhesion, 2003, 10, 85-103.	1.0	12
80	High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Research, 2003, 63, 8749-56.	0.4	138
81	The Level of Syndecan-1 Expression is a Distinguishing Feature in Behavior between Keratoacanthoma and Invasive Cutaneous Squamous Cell Carcinoma. Modern Pathology, 2002, 15, 45-49.	2.9	36
82	Syndecan-1 is Strongly Expressed in the Anagen Hair Follicle Outer Root Sheath and in the Dermal Papilla but Expression Diminishes With Involution of the Hair Follicle. American Journal of Dermatopathology, 2002, 24, 484-489.	0.3	24
83	Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002, 100, 610-617.	0.6	178
84	Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood, 2002, 99, 1745-1757.	0.6	590
85	Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood, 2002, 100, 3002-3007.	0.6	227
86	Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Research, 2002, 62, 3722-8.	0.4	47
87	Heparan sulfate proteoglycans in invasion and metastasis. Seminars in Cell and Developmental Biology, 2001, 12, 89-98.	2.3	200
88	Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions. Modern Pathology, 2001, 14, 1052-1058.	2.9	117
89	Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfateâ€"mediated cell-cell adhesion. Blood, 2001, 98, 2160-2165.	0.6	53
90	Acantholysis and spongiosis are associated with loss of syndecan-1 expression. Journal of Cutaneous Pathology, 2001, 28, 135-139.	0.7	17

#	Article	IF	Citations
91	Matrix Metalloproteinases in Multiple Myeloma. Leukemia and Lymphoma, 2000, 37, 273-281.	0.6	48
92	Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood, 2000, 96, 2528-2536.	0.6	103
93	High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood, 2000, 96, 3139-3146.	0.6	91
94	The Cysteine-Rich Domain of Human Adam 12 Supports Cell Adhesion through Syndecans and Triggers Signaling Events That Lead to Î²1 Integrinâ€“Dependent Cell Spreading. Journal of Cell Biology, 2000, 149, 1143-1156.	2.3	244
95	Syndecan-1 Expression Is Decreased With Increasing Aggressiveness of Basal Cell Carcinoma. American Journal of Dermatopathology, 2000, 22, 119-122.	0.3	41
96	Syndecan-1 (CD 138) in Myeloma and Lymphoid Malignancies: A Multifunctional Regulator of Cell Behavior Within the Tumor Microenvironment. Leukemia and Lymphoma, 1999, 34, 35-43.	0.6	50
97	Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. British Journal of Haematology, 1999, 104, 365-373.	1.2	30
98	Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma. Journal of Cutaneous Pathology, 1999, 26, 386-390.	0.7	26
99	Syndecan-1 Expression Is Induced in the Stroma of Infiltrating Breast Carcinoma. American Journal of Clinical Pathology, 1999, 112, 377-383.	0.4	118
100	Heparan Sulfate Proteoglycans as Adhesive and Anti-invasive Molecules. Journal of Biological Chemistry, 1998, 273, 22825-22832.	1.6	144
101	Multiple Heparan Sulfate Chains Are Required for Optimal Syndecan-1 Function. Journal of Biological Chemistry, 1998, 273, 29965-29971.	1.6	83
102	Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. British Journal of Haematology, 1997, 99, 368-371.	1.2	94
103	Heparan Sulfate-mediated Cell Aggregation. Journal of Biological Chemistry, 1995, 270, 5077-5083.	1.6	98
104	Syndecans as Anti-invasive Molecules on the Surface of Tumor Cells.. Trends in Glycoscience and Glycotechnology, 1995, 7, 513-524.	0.0	1
105	Interleukin-6 Regulates Expression of the Syndecan-1 Proteoglycan on B Lymphoid Cells. Cellular Immunology, 1994, 153, 456-467.	1.4	37
106	Syndecan-1, a Cell-Surface Proteoglycan, Changes in Size and Abundance when Keratinocytes Stratify. Journal of Investigative Dermatology, 1992, 99, 390-396.	0.3	87
107	Functional and molecular characterization of single, (4-hydroxy-3-nitrophenyl)acetyl (NP)-specific, IgG1+ B cells from antibody-secreting and memory B cell pathways in the C57BL/6 immune response to NP. European Journal of Immunology, 1992, 22, 3001-3011.	1.6	169
108	Epithelial-mesenchymal interactions in uterus and vagina alter the expression of the cell surface proteoglycan, syndecan. Developmental Biology, 1991, 148, 63-74.	0.9	59

#	Article	IF	Citations
109	The Extracellular Matrix of Skeletal Muscle. Collagen and Related Research, 1985, 5, 449-468.	2.2	58
110	Changes in the synthesis of minor cartilage collagens after growth of chick chondrocytes in 5-bromo-2â€²-deoxyuridine or to senescence. Experimental Cell Research, 1984, 151, 171-182.	1.2	26